Skip to main content

Galmed Pharmaceuticals Ltd. (GLMD)

NASDAQ: GLMD · IEX Real-Time Price · USD
3.05 0.03 (0.99%)
Sep 23, 2021 4:00 PM EDT - Market closed
Market Cap75.75M
Revenue (ttm)n/a
Net Income (ttm)-34.48M
Shares Out25.08M
EPS (ttm)-1.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume57,585
Open3.01
Previous Close3.02
Day's Range2.94 - 3.09
52-Week Range2.15 - 6.25
Beta2.22
AnalystsBuy
Price Target17.80 (+483.6%)
Est. Earnings DateNov 11, 2021

About GLMD

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it eng...

IndustryBiotechnology
IPO DateMar 13, 2014
CEOAllen Baharaff
Employees18
Stock ExchangeNASDAQ
Ticker SymbolGLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for GLMD stock is "Buy." The 12-month stock price forecast is 17.80, which is an increase of 483.61% from the latest price.

Price Target
$17.80
(483.61% upside)
Analyst Consensus: Buy

News

Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER is a five amino acid in a specific seque...

1 month ago - Benzinga

Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specif...

TEL AVIV, Israel, Aug. 19, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

1 month ago - PRNewsWire

MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of th...

TEL AVIV, Israel, Aug. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

1 month ago - PRNewsWire

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

TEL AVIV, Israel, Aug. 5, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver ...

1 month ago - PRNewsWire

Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial

The FDA has agreed with Galmed Pharmaceuticals Ltd's (NASDAQ: GLMD) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR study without the need for additional studies othe...

1 month ago - Benzinga

FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the...

TEL AVIV, Israel, Aug. 2, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory di...

1 month ago - PRNewsWire

Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5

TEL AVIV, Israel, July 29, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol,...

1 month ago - PRNewsWire

Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results

TEL AVIV, Israel, May 13, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver ...

4 months ago - PRNewsWire

Galmed Pharmaceuticals to Report First Quarter 2021 Financial Results and Provide Business Update on Thursday May 13

TEL AVIV, Israel, May 6, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a...

4 months ago - PRNewsWire

Galmed Announces Approval of IND Application in China for Aramchol for the Treatment of NASH & Fibrosis in the Global...

TEL AVIV, Israel, May 3, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory dis...

4 months ago - PRNewsWire

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results

TEL AVIV, Israel, March 18, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live...

6 months ago - PRNewsWire

Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER

TEL AVIV, Israel, March 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the f...

6 months ago - PRNewsWire

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Th...

TEL AVIV, Israel, March 11, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol...

6 months ago - PRNewsWire

Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares

TEL AVIV, Israel, Feb. 16, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

7 months ago - PRNewsWire

Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fi...

TEL AVIV, Israel, Jan. 26, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

7 months ago - PRNewsWire

Galmed to add Open Label Part to ARMOR Study; First Read-out Expected in Q4 2021

TEL AVIV, Israel, Dec. 17, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory d...

9 months ago - PRNewsWire

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q3 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Galmed and Gannex Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta...

TEL-AVIV, Israel and SHANGHAI, Sept. 10, 2020 /PRNewswire/ -- Gannex Pharma Co.

1 year ago - PRNewsWire

Gannex and Galmed Expand Development Programs For NASH Through Research Collaboration of Aramchol and ASC41 (THR-beta...

SHANGHAI and TEL-AVIV, Israel, Sept. 9, 2020 /PRNewswire/ -- Gannex Pharma Co.

1 year ago - PRNewsWire

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd. (GLMD) CEO Allen Baharaff on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

1 year ago - PRNewsWire

Galmed Pharmaceuticals Announces Acceleration of its New Clinical Amilo-5MER program

TEL AVIV, Israel, Aug. 6, 2020 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

1 year ago - PRNewsWire

How Galmed (GLMD) Stock Stands Out in a Strong Industry

Galmed (GLMD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q1 2020 Results - Earnings Call Transcript

Galmed Pharmaceuticals Ltd (GLMD) CEO Allen Baharaff on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Galmed Pharmaceuticals Provides Business Update and Reports First Quarter 2020 Financial Results

TEL AVIV, Israel, May 14, 2020 /PRNewswire/ --Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver t...

1 year ago - PRNewsWire